companies

Kiro

Founded 2019
Employees 10+
Primary contact
1 rue de la Bourse
75002 Paris
Île-de-France
France
Links
https://www.kiro.bio/
Sections
Technologies
Kiro claims to be the first AI-powered digital health platform for clinical biology in Europe. It is committed to developing new approaches to medical biology using medical-grade AI and cloud technology and leverages laboratory results to bring better outcomes for patients. Developed in partnership with leading laboratories, hospitals and physicians, and already used by millions of users - Kiro's solutions provide personalized and easy-to-understand results for patients and caregivers while helping healthcare providers better follow and treat their patients with real-time clinical decision support tools. The company's AI model was trained on more than 26 million lab reports to detect the early onset of diseases.
Founded 2019
Employees 10+
Primary contact
1 rue de la Bourse
75002 Paris
Île-de-France
France
Links
https://www.kiro.bio/
Sections
Technologies

Funding 💰

Total €17M
Last round 🔗 €13.8M
Series A
March 28, 2023.
Select investors Sofinnova Partners, Kurma Partners, Bpifrance, Propulia Capital, Kima Ventures

Key people 🧑‍🤝‍🧑

Highlights ⭐

  • Report generation in seconds: Medically validated, Kiro can help interpret data from a broad range of lab tests and generate a report within seconds, enabling faster and more efficient patient care and empowering clinicians worldwide to better deliver their expertise.
  • Strong product usage: As of March 2023, Kiro had more than 150,000 monthly active users.
  • Expansion plans: On the heels of its Series A round of funding, the company said it plans to expand commercial operations in Europe and prepare entry into the US market. 🔗

Awards & Recognitions 🏆

  • 2020 Investissement D'Avenir
  • 2020 Netva Deep Tech North America
  • 2019 Concours National De L'Innovation i-Lab
  • 2019 Bpifrance Excellence

Quotes 💬

“
Kiro has the potential to combine laboratory tests with machine and deep learning algorithms to transform medical biology into a tool that empowers physicians and patients alike. We look forward to working with Alex and the team to revolutionize precision care: getting the right treatment for the right patient at the right time, but also in the right format - one that really talks to the patients themselves and makes them part of the journey.
— Edward Kliphuis, Partner at Sofinnova Partners 🔗
Last update: May 9, 2023